Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Acasti Pharma Inc. (ACST)

0.6691   -0.023 (-3.37%) 01-24 16:00
Open: 0.6801 Pre. Close: 0.6924
High: 0.685 Low: 0.6575
Volume: 1,699,734 Market Cap: 58M
Acasti Pharma Inc is a biopharmaceutical company. The Company is engaged in the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of cardiometabolic disorders.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.691 - 0.695 0.695 - 0.7
Low: 0.649 - 0.653 0.653 - 0.658
Close: 0.662 - 0.669 0.669 - 0.677

Technical analysis

as of: 2020-01-24 4:29:20 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.45     One year: 3.60
Support: Support1: 0.51    Support2: 0.42
Resistance: Resistance1: 2.10    Resistance2: 3.08
Pivot: 1.36
Moving Average: MA(5): 0.71     MA(20): 1.65
MA(100): 1.96     MA(250): 1.52
MACD: MACD(12,26): -0.42     Signal(9): -0.29
Stochastic oscillator: %K(14,3): 8.85     %D(3): 9.18
RSI: RSI(14): 27.51
52-week: High: 3.08  Low: 0.51  Change(%): -38.0
Average Vol(K): 3-Month: 462995  10-Days: 1037689

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
ACST has closed above bottom band by 26.4%. Bollinger Bands are 291.7% wider than normal. The large width of the bands suggest high volatility as compared to ACST's normal range. The bands have been in this wide range for 9 bars. This is a sign that the current trend might continue.

Headline News

Acasti Shares Slump On Failed Late-Stage Trial, Amarin Moves In Sympathy
Shares of Acasti Pharma Inc (NASDAQ: ACST ), which closed at $2.18 Friday, have entered penny stock territory after a negative data readout. Placebo Effect Impacts Acasti's Results Acasti released topline results Monday from a Phase 3 study dubbed TRILOGY 1 that evaluated its lead candidate CaPre, or omega-3 phospholipid, for the treatment of hypertriglyceridemia. The experimental drug did not achieve statistical significance in meeting the primary endpoint. This was due to unusually large placebo effect, according to the company. CaPre reduced triglyceride by 30% from the baseline at 12 weeks and by 36.7% at 26 weeks, the company said. The control arm receiving placebo showed a 27.5% mean reduction in triglyceride levels at 12 weeks and a 28% mean reduction at week 26. Patients receiving CaPre while on background statin therapy showed a 42.2% mean reduction in triglyceride at 12 weeks compared to 31.5% for … Full story available on

Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short
AstraZeneca and Acasti Pharma each disclosed disappointing results from cardiovascular drugs derived from fish or krill oil. Amarin’s stock took off.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 87.95
Shares Float (M) 72.03
% Held by Insiders 15.55
% Held by Institutions 4.55
Shares Short (K) 1740
Shares Short P. Month (K)

Stock Financials

EPS -1.224
Book Value (p.s.) -0.300
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -90.5
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E -0.55
P/E Growth Ratio -0.03
P/BV -2.23

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2015-10-14
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.